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Summary We examined the usefulness of some bronchial reactivity indices to
identify bronchial asthma in patients with airway hyperresponsiveness.
Eighty-eight consecutive patients with positive response to histamine bronchial
challenge (X20% fall in FEV1) were included in the study. Dose–response curves were
characterised by their sensitivity (PD20) and reactivity. Dose–response slope,
continuous index of responsiveness (CIR) and bronchial reactivity index (BRI) with
respect to baseline and post-diluent baseline values were determined as reactivity
indices. The clinical diagnosis remaining in the case history 2 years after the bronchial
challenge was considered the definitive diagnosis.
Asthmatic patients had higher baseline BRI (12.12170.412 vs. 11.61570.201;
Po0:001) and post-diluent baseline BRI (12.05470.368 vs. 11.56370.531; P ¼ 0:003)
than other subjects. Area beneath their receiver operating characteristic (ROC) curve
was 82.68% (standard error: 0.77) for the baseline BRI and 81.73 (standard error:
0.76). By multiple logistic regression analysis, baseline BRI was the only independent
variable identified as a predictor for diagnosis of bronchial asthma (r ¼ 0:387;
P ¼ 0:0007). A cut-off of 11.76 for baseline BRI reached an 87.2% sensitivity and an
80% specificity for bronchial asthma diagnosis.
In conclusion, BRI calculated with respect to baseline FEV1 should be useful in
identifying asthmatic patients among subjects with airway hyperresponsiveness.
& 2003 Elsevier Ltd. All rights reserved.
Introduction
Airway hyperresponsiveness, defined as an exag-
gerated airway narrowing upon exposure to a non-
specific bronchoconstrictor stimuli, is a functional
phenomenon associated with inflammatory disor-
ders of the airways, such as asthma.1–6
Airway hyperresponsiveness is usually studied by
constructing dose–response curves to pharmacolo-
gical bronchoconstrictors.7 Conventional indices of
responsiveness derived from the dose–response
curve have been reported using various methods.
Hypersensitivity and hyperreactivity specifically
refer to a leftward shift and an increase in slope,
respectively, of the dose–response curve obtained
during inhalation challenge procedures.8
Most commonly, the dose–response relationship
is described as the dose or concentration of
bronchoconstricting agent that causes a specified
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decline in airflow or airway conductance, such as
PD20 FEV1, the dose provoking a 20% decline in
FEV1.
7,9 These measurements are related to asthma
severity and provide a useful measure with which
to follow the course of individual asthmatic
patients.10
However, these expressions of responsiveness
have an important limitation in diagnostic proce-
dures for asthma. They are particularly suitable for
the exclusion of asthma, because of the high
sensitivity and high negative predictive value.
However, since airway hyperresponsiveness is also
described in allergic rhinitis, cystic fibrosis, viral
infections, influenza vaccination, congestive
hearth failure, sarcoidosis, bronchopulmonary dys-
plasia, hypersensitivity pneumonitis, chronic ob-
structive pulmonary disease, antigen exposure,
outdoor pollution (ozone, NO2, SO2) and healthy
subjects,4,11–15 a positive result is not a pre-
requisite of asthma, and hence, does not rule out
other conditions.
An alternative method of expressing the dose–
response relationship involves fitting a mathema-
tical model to each individual subject’s data.
Simple and more complicated models have been
used to describe the shape of the dose–response
curve.3,7,16,17 It has been proposed that the dose–
response curve slope could be more useful in the
identification of asthmatic patients than the
determination of threshold dose or sensitivity.8,18
In the present report, we examine the usefulness
of some bronchial reactivity indices in identifying
bronchial asthma in patients with airway hyperre-
sponsiveness.
Methods
Subjects
Eighty-eight consecutive patients with positive
response to histamine bronchial challenge (X20%
fall in FEV1) were included in the study. Patients
were referred to bronchial challenge due to clinical
suspicion of asthma. There were 55 women and 33
men, with an age (mean 7 standard deviation (SD))
of 38718 years. Their weight and height were
65715 kg and 162719 cm, respectively. Sixteen
subjects (18%) were smokers at the time of the
study.
Patients stopped use of short- or long-acting
beta2-adrenergic bronchodilators for at least 12 or
24 h before the bronchial challenge, respectively.
Antihistamine had been withdrawn for at least 1
week before the bronchial challenge. None of the
subjects had taken inhaled or oral corticosteroids
or leukotriene receptor antagonists in the 3 months
before the study. Informed consent was obtained
from all subjects.
Pulmonary function
Spirometry was conducted with a MasterScreen
Pneumo 4.2 (Jaeger, W .urzburg, Germany) accord-
ing to European Respiratory Society standardisa-
tion.19 The normal values for lung volumes were
those proposed by the European Community for
Coal and Steel.20
A standardised dosimeter technique was used for
histamine challenge.7 Bronchial aerosol provoca-
tion system (APS, Jaeger, W .urzburg, Germany) with
Medic Aid Side Stream nebuliser (Medic-Aid Ltd,
Bognor Regis, UK) was used for this procedure. The
nebuliser was calibrated to produce an output of
160mg/ml, with an airflow rate of 100ml/s. A flow
sensor in the expiratory port triggers a solenoid
which exposes the nebuliser to compressed air at
138 kPa (20 psi) for about 0.6 s, to give a calibrated
output per puff of 9.0 ml. The nebuliser generates
heterodisperse droplets with a median aerody-
namic mass diameter of 0.5–4 mm.
Each subject was instructed to inhale the
aerosols by taking slow deep breaths from func-
tional residual capacity to inspiratory capacity
without breathholding. The first aerosol was 0.9%
saline followed by doubling doses of histamine
diphosphate from 0.03 to 9.4mmol. A 3-min
interval was allowed before each dose increment.
FEV1 was measured by a MasterScreen Pneumo
(Jaeger) 2min after each dose and the highest of
three acceptable measurements within 100ml was
retained to create dose–response curves. The test
was discontinued when there was a fall in FEV1 of
X20% compared with the control inhalation (0.9%
saline solution) or until the maximal dose was
inhaled.
Dose–response curves were plotted for each
challenge test as percentage fall in FEV1 against
the dose of histamine on a log scale and were
characterised by their sensitivity (dose of histamine
that produced 20% fall in FEV1, PD20) and their
slope. When FEV1 had fallen by X20% from post-
diluent baseline value, the challenge was consid-
ered positive and PD20 was determined by linear
extrapolation on a semi-logarithmic scale. Dose–
response slope (DRS) was summarised as the
expression: per cent decline FEV1/dose, where
per cent decline FEV1 was defined as the decline
in FEV1 (from the baseline and post-diluent base-
line values) after the final histamine dose was
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administered, and dose was defined as the final
cumulative dose administered.16 Continuous index
of responsiveness (CIR) was determined as the
logarithm of the per cent decline from the pre- and
post-diluent baseline FEV1 after the last dose of
histamine per unit dose of histamine.17 Finally,
bronchial reactivity index (BRI) was defined as the
log of the per cent decline in FEV1/log final
histamine dose after adding 10 to eliminate
negative values.17
Clinical diagnosis
A physician blinded to the results from the analysis
of airway reactivity indices revised the case history
of each patient included in the study. Asthma was
defined as a clinical history of intermittent wheeze,
cough, chest tightness, or dyspnoea, and documen-
ted reversible airflow limitation either sponta-
neously or with treatment.1 Definitive diagnosis
was established after a follow-up of 2 years, as the
clinical diagnosis remaining in the case history.
Statistical analysis
Data are expressed as mean7SD. The statistical
study was performed using the Statistical Package
for the Social Sciences software for Windows
Release 8.0 (SPSS Inc, Chicago, IL, USA). The
quantitative parameters for groups with and with-
out asthma were compared by t-test or Mann–
Whitney test. For comparison of qualitative vari-
ables, the w2 test was applied. Po0:05 was
considered significant.21 Analysis of the individual
variables was completed by calculating the areas
beneath their receiver operating characteristic
(ROC) curves.22 Logistic regression was used to
assess interaction between the most significant
variables with respect to asthma diagnosis.23
Results
A definitive diagnosis of bronchial asthma was
reached in 55 patients (63%). The 33 remaining
subjects were considered to have allergic rhinitis
(20 cases), post-infectious airway hyperresponsive-
ness (11 cases) or absence of recognised respiratory
disease after the 2 years of follow-up (two cases).
No significant differences in anthropometric
characteristics, smoking habit, baseline FEV1,
post-diluent fall in FEV1 or PD20 were noted
between asthmatic patients and non-asthmatic
subjects. However, asthmatic patients had higher
baseline BRI (12.12170.412 vs. 11.61570.201;
Po0:001) and post-diluent BRI (12.05470.368 vs.
11.56370.531; P ¼ 0:003) than the other subjects
(Table 1).
Area beneath ROC curve was 82.68% (standard
error: 0.77) for the baseline BRI and 81.73
(standard error: 0.76) (Fig. 1). By multiple logistic
regression analysis, baseline BRI was the only
independent variable identified as a predictor in
the diagnosis of bronchial asthma (r ¼ 0:387;
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Table 1 Anthropometric and functional characteristics of asthma and non-asthma groups.n
Asthma group (n ¼ 55) Non-asthma group (n ¼ 33)
Females (%) 63.6 39.4
Age (years) 39717 36719
Height (cm) 161722 164711
Weight (kg) 65713 69718
Current smokers (%) 18.2 18.2
Atopic subjects (%) 42 48
Baseline FVC (l) 3.6571.10 3.7571.29
Baseline FEV1 (l) 2.9970.93 3.0171.04
Baseline FEV1/FVC (%) 81.976.7 81.1712.1
Post-diluent FEV1 (l) 2.8770.97 2.9570.96
PD20 (mmol) 3.3172.40 2.2171.98
Baseline DRS (%/mmol) 106.57375.4 150.27550.8
Post-diluent DRS (%/mmol) 75.47196.6 84.37243.4
Baseline CIR 1.3970.53 1.4070.73
Post-diluent CIR 1.3570.51 1.3070.74
Baseline BRI 12.12170.412 11.61570.201w
Post-diluent BRI 12.05470.368 11.56370.531w
nResults are mean7SD.
wPo0:001 vs. asthma group.
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P ¼ 0:0007). The best cut-off of baseline BRI to
discriminate between asthmatic and non-asthmatic
subjects was 11.76. This point reached an 87.2%
sensitivity and an 80% specificity for diagnosing
bronchial asthma (Fig. 2).
Discussion
The main result of our study consists in the
identification of BRI as a discriminatory factor
between asthmatic and non-asthmatic subjects
with airway hyperresponsiveness. In our patients,
the BRI calculated with respect to baseline FEV1
have a notable diagnostic sensitivity and specificity.
An important methodological issue needs prior
comment. We considered the definitive diagnosis of
our patients as that which remained in the case
history after a 2-year follow-up. In our opinion, this
has two important implications. Diagnosis of each
patient was established by a physician outside the
study according to standard criteria.1 With this
procedure, we tended to avoid bias in subject
classification. The objective of the 2-year follow-up
was to assess the airway hyperresponsiveness by
discriminating between permanent and transitory
cases. Moreover, previous studies described that up
to 19% of patients with allergic rhinitis and airway
hyperresponsiveness develop bronchial asthma in
the 2 years following diagnosis.24 Thus, it seems
reasonable to follow the clinical evolution of
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Figure 1 ROC curves for the ability of baseline and post-diluent BRI to distinguish between patients with asthma and
subjects without asthma. The ordinate represents the conditional probability of a correct suspicion of asthma, while
the abscissa represents the conditional probability of a false suspicion.
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Figure 2 Sensitivity and specificity of baseline BRI in identifying bronchial asthma.
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patients during this period before establishing the
definitive diagnosis.
Classical analysis of bronchial challenge curves in
terms of PD20 sensitivity proposes an important
problem. The majority of methacholine or hista-
mine bronchial challenge tests are characterised by
a unimodal or continuous distribution of airway
sensitivity.25 This disposition, without a clear cut-
off between studied populations, makes it an
unlikely choice for the normal threshold. There-
fore, any cut-off chosen will define sensitivity and
specificity levels to discriminate between asth-
matic and non-asthmatic subjects. This point must
be considered arbitrary and variable in relation to
population studied and method applied.
Although sensitivity analysis of bronchial chal-
lenge has an elevated negative predictive value, its
positive predictive value is very dependent on
degree of clinical suspicion. For an asthma pre-test
probability of 50%, the probability of having asthma
when the challenge is positive reaches 86%.26
However, after a 2-year follow-up, diagnosis of
bronchial asthma was only reported in 39% of
asymptomatic subjects with bronchial hyperrespon-
siveness.27 Our patients are in an intermediate
situation, because bronchial hyperresponsiveness
was associated with bronchial asthma diagnosis in
63%.
Contrasting with recognised limitations of the
sensitivity analysis of bronchial challenge dose–
response curve, our results show that the reactivity
analysis could contribute to better discrimination
between asthmatic and non-asthmatic patients.
Differences in diagnostic accuracy among the
various bronchial reactivity indices analysed should
be attributed to their interval characteristics. DRS
is a simple expression that summarises each
subject’s dose–response relationship by the slope
of a line connecting the origin of the dose–response
curve with the final point of the curve. Previously,
it has been shown that a linear model fits histamine
dose–response data better than does a logarithmic
model.28 Therefore, within the dose range exam-
ined, there is a strong linear relationship between
dose and per cent decline in FEV1 for asthmatic
subjects.16 A previous study16 reported that DRS
differed markedly between asthmatic and normal
subjects. But not one of the nine normal subjects in
their study showed airway hyperresponsiveness,
determined by a 20% decline in FEV1. In contrast,
after adding a constant of 10 to eliminate negative
numbers, BRI provides a most continuous and
relatively normally distributed index of bronchial
reactivity. In a study over 522 11-year-old children,
reported asthma was associated with increased BRI
independent of other factors such as serum IgE
levels, symptoms or sex.17 Therefore, it is possible
that BRI has better discriminatory power between
asthmatics and non-asthmatics as a consequence of
its better adjustment to normal distribution.
The convenience of analysing bronchial challenge
dose–response curve with respect to pre- or post-
diluent baseline values is still controversial.29,30
From a theoretical point of view, the indices
calculated with respect to post-diluent better
represent the challenge effect than those calcu-
lated with respect to baseline value. The former
reflect only the changes induced by the bronchial
challenge, whereas the latter are influenced by
challenge and diluent nebulisation.7 However, in
our study, baseline BRI was the only independent
variable with diagnostic predictive capacity.
There is evidence that maximum capacity and
velocity of shortening in bronchial smooth muscles
in patients with asthma are significantly greater
than those obtained in healthy subjects.31,32 More-
over, it has been demonstrated that the increased
extent of shortening in sensitised airway smooth
muscles occurs in the early phase of shortening.
These findings should explain the greater BRI found
in our asthmatic patients. An unresolved question is
whether bronchial smooth muscle contractility is
altered or if the muscle is made to shorten more
simply by increased amounts of agonists released
from the mast cells and other cells by the immune
reaction. Nevertheless, and due to the phenotypic
heterogeneity of bronchial smooth muscle cells, a
different cellular composition should also justify
the faster shortening of bronchial muscle in
patients with bronchial asthma.
Moreover, our results are in accordance with
previous results of other studies with different
dose–response curve analyses. Prieto et al.33 per-
formed a methacholine bronchial challenge in
asthmatic patients and in subjects with rhinitis.
These authors administered higher doses of metha-
choline just to achieve a maximal response,
characterised by a plateau level of FEV1. In their
study, fall in FEV1 in asthmatics was faster than in
subjects with rhinitis.33
In conclusion, due to the low positive predictive
value of histamine bronchial challenge for diagnos-
ing asthma, reactivity index analysis should con-
tribute to the identification of asthmatic patients
among those subjects with airway hyperresponsive-
ness. Reactivity analysis is neither expensive nor
invasive. Its determination is easy and does not
require modifying challenge tests. However, it must
be considered that the cut-off point obtained in our
study could not be applied in other population
groups and that its diagnostic accuracy will depend
on the prevalence of bronchial asthma in each
ARTICLE IN PRESS
Bronchial reactivity in asthma 203
group or, in other words, on the degree of clinical
suspicion.
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